These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

252 related articles for article (PubMed ID: 37163614)

  • 1. Immune checkpoint B7-H3 is a therapeutic vulnerability in prostate cancer harboring PTEN and TP53 deficiencies.
    Shi W; Wang Y; Zhao Y; Kim JJ; Li H; Meng C; Chen F; Zhang J; Mak DH; Van V; Leo J; St Croix B; Aparicio A; Zhao D
    Sci Transl Med; 2023 May; 15(695):eadf6724. PubMed ID: 37163614
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Targeting DNA methylation and B7-H3 in RB1-deficient and neuroendocrine prostate cancer.
    Yamada Y; Venkadakrishnan VB; Mizuno K; Bakht M; Ku SY; Garcia MM; Beltran H
    Sci Transl Med; 2023 Nov; 15(722):eadf6732. PubMed ID: 37967200
    [TBL] [Abstract][Full Text] [Related]  

  • 3. B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity.
    Yonesaka K; Haratani K; Takamura S; Sakai H; Kato R; Takegawa N; Takahama T; Tanaka K; Hayashi H; Takeda M; Kato S; Maenishi O; Sakai K; Chiba Y; Okabe T; Kudo K; Hasegawa Y; Kaneda H; Yamato M; Hirotani K; Miyazawa M; Nishio K; Nakagawa K
    Clin Cancer Res; 2018 Jun; 24(11):2653-2664. PubMed ID: 29530936
    [No Abstract]   [Full Text] [Related]  

  • 4. B7-H3 Promotes Prostate Cancer Progression in Mice by Antagonizing Myeloid-Derived Suppressor Cell Apoptosis.
    Zhou Y; Zhang G; Zhang W; Wei X; Hou J; Huang Y
    Technol Cancer Res Treat; 2020; 19():1533033820971649. PubMed ID: 33280506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Co-targeting hexokinase 2-mediated Warburg effect and ULK1-dependent autophagy suppresses tumor growth of PTEN- and TP53-deficiency-driven castration-resistant prostate cancer.
    Wang L; Wang J; Xiong H; Wu F; Lan T; Zhang Y; Guo X; Wang H; Saleem M; Jiang C; Lu J; Deng Y
    EBioMedicine; 2016 May; 7():50-61. PubMed ID: 27322458
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting Radiation-Resistant Prostate Cancer Stem Cells by B7-H3 CAR T Cells.
    Zhang Y; He L; Sadagopan A; Ma T; Dotti G; Wang Y; Zheng H; Gao X; Wang D; DeLeo AB; Fan S; Sun R; Yu L; Zhang L; Wang G; Ferrone S; Wang X
    Mol Cancer Ther; 2021 Mar; 20(3):577-588. PubMed ID: 33653946
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune checkpoint B7-H3 protein expression is associated with poor outcome and androgen receptor status in prostate cancer.
    Nunes-Xavier CE; Kildal W; Kleppe A; Danielsen HE; Waehre H; Llarena R; Maelandsmo GM; Fodstad Ø; Pulido R; López JI
    Prostate; 2021 Sep; 81(12):838-848. PubMed ID: 34125445
    [TBL] [Abstract][Full Text] [Related]  

  • 8. B7-H3/CD276: An Emerging Cancer Immunotherapy.
    Zhou WT; Jin WL
    Front Immunol; 2021; 12():701006. PubMed ID: 34349762
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Paucity of PD-L1 expression in prostate cancer: innate and adaptive immune resistance.
    Martin AM; Nirschl TR; Nirschl CJ; Francica BJ; Kochel CM; van Bokhoven A; Meeker AK; Lucia MS; Anders RA; DeMarzo AM; Drake CG
    Prostate Cancer Prostatic Dis; 2015 Dec; 18(4):325-32. PubMed ID: 26260996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer.
    Mendes AA; Lu J; Kaur HB; Zheng SL; Xu J; Hicks J; Weiner AB; Schaeffer EM; Ross AE; Balk SP; Taplin ME; Lack NA; Tekoglu E; Maynard JP; De Marzo AM; Antonarakis ES; Sfanos KS; Joshu CE; Shenderov E; Lotan TL
    Cancer; 2022 Jun; 128(12):2269-2280. PubMed ID: 35333400
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correlation of expression of Major Vault Protein with androgen receptor and immune checkpoint protein B7-H3, and with poor prognosis in prostate cancer.
    Nunes-Xavier CE; Emaldi M; Guldvik IJ; Ramberg H; Taskén KA; Mælandsmo GM; Fodstad Ø; Llarena R; Pulido R; López JI
    Pathol Res Pract; 2023 Jan; 241():154243. PubMed ID: 36481650
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effective combinatorial immunotherapy for castration-resistant prostate cancer.
    Lu X; Horner JW; Paul E; Shang X; Troncoso P; Deng P; Jiang S; Chang Q; Spring DJ; Sharma P; Zebala JA; Maeda DY; Wang YA; DePinho RA
    Nature; 2017 Mar; 543(7647):728-732. PubMed ID: 28321130
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of targeted AKT inhibition in genetically engineered mouse models of PTEN-deficient prostate cancer.
    De Velasco MA; Kura Y; Yoshikawa K; Nishio K; Davies BR; Uemura H
    Oncotarget; 2016 Mar; 7(13):15959-76. PubMed ID: 26910118
    [TBL] [Abstract][Full Text] [Related]  

  • 14. B7-H3 as a Therapeutic Target in Advanced Prostate Cancer.
    Guo C; Figueiredo I; Gurel B; Neeb A; Seed G; Crespo M; Carreira S; Rekowski J; Buroni L; Welti J; Bogdan D; Gallagher L; Sharp A; Fenor de la Maza MD; Rescigno P; Westaby D; Chandran K; Riisnaes R; Ferreira A; Miranda S; Calì B; Alimonti A; Bressan S; Nguyen AHT; Shen MM; Hawley JE; Obradovic A; Drake CG; Bertan C; Baker C; Tunariu N; Yuan W; de Bono JS
    Eur Urol; 2023 Mar; 83(3):224-238. PubMed ID: 36114082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. B7-H3/CD276 Inhibitors: Is There Room for the Treatment of Metastatic Non-Small Cell Lung Cancer?
    Malapelle U; Parente P; Pepe F; Di Micco MC; Russo A; Clemente C; Graziano P; Rossi A
    Int J Mol Sci; 2022 Dec; 23(24):. PubMed ID: 36555714
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of the B7-H3 immune checkpoint limits tumor growth by enhancing cytotoxic lymphocyte function.
    Lee YH; Martin-Orozco N; Zheng P; Li J; Zhang P; Tan H; Park HJ; Jeong M; Chang SH; Kim BS; Xiong W; Zang W; Guo L; Liu Y; Dong ZJ; Overwijk WW; Hwu P; Yi Q; Kwak L; Yang Z; Mak TW; Li W; Radvanyi LG; Ni L; Liu D; Dong C
    Cell Res; 2017 Aug; 27(8):1034-1045. PubMed ID: 28685773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. B7 score and T cell infiltration stratify immune status in prostate cancer.
    Zhou Q; Li K; Lai Y; Yao K; Wang Q; Zhan X; Peng S; Cai W; Yao W; Zang X; Xu K; Huang J; Huang H
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34417325
    [TBL] [Abstract][Full Text] [Related]  

  • 18. SKP2 loss destabilizes EZH2 by promoting TRAF6-mediated ubiquitination to suppress prostate cancer.
    Lu W; Liu S; Li B; Xie Y; Izban MG; Ballard BR; Sathyanarayana SA; Adunyah SE; Matusik RJ; Chen Z
    Oncogene; 2017 Mar; 36(10):1364-1373. PubMed ID: 27869166
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting the immune checkpoint B7-H3 for next-generation cancer immunotherapy.
    Liu C; Zhang G; Xiang K; Kim Y; Lavoie RR; Lucien F; Wen T
    Cancer Immunol Immunother; 2022 Jul; 71(7):1549-1567. PubMed ID: 34739560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pan-Cancer Interrogation of B7-H3 (CD276) as an Actionable Therapeutic Target Across Human Malignancies.
    Miller CD; Lozada JR; Zorko NA; Elliott A; Makovec A; Radovich M; Heath EI; Agarwal N; Mckay RR; Garje R; Bastos BR; Hoon DSB; Orme JJ; Sartor O; VanderWalde A; Nabhan C; Sledge G; Shenderov E; Dehm SM; Lou E; Miller JS; Hwang JH; Antonarakis ES
    Cancer Res Commun; 2024 May; 4(5):1369-1379. PubMed ID: 38709075
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.